Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation.

Abstract

We report a case of imatinib- and nilotinib-resistant Ph-positive chronic myeloid leukemia (CML) in blast crisis in which successful pretreatment with dasatinib with cord blood transplantation resulted in molecular remission. Before dasatinib therapy, the patient was found to have a F359V BCR-ABL mutation. He was treated with dasatinib for just 16, 19 days before allogeneic stem cell transplantation. This successful case indicates that reduction of tumor burden by second-generation tyrosine kinase inhibitors, in combination with stem cell transplantation, might be effective to treat CML, even in the advanced phase.

• Authors: Moritaka Gotoh, Tetsuzo Tauchi, Seiichiro Yoshizawa, Toshihiko Kitahara, Toru Kiguchi, Yukihiko Kimura, Kazuma Ohyashiki
• Journal: International journal of hematology (Int J Hematol) Vol. 91 Issue 1 Pg. 128-31 (Jan 2010) ISSN: 1865-3774 [Electronic] Japan
• PMID: 20047099 (Publication Type: Case Reports, Journal Article)

Chemical References

• Protein Kinase Inhibitors
• Pyrimidines
• Thiazoles
• Fusion Proteins, bcr-abl
• Dasatinib

Topics

• Blast Crisis (drug therapy, genetics, pathology)
• Cord Blood Stem Cell Transplantation
• Dasatinib
• Fusion Proteins, bcr-abl (genetics)
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, genetics, pathology)
• Male
• Middle Aged
• Protein Kinase Inhibitors (administration & dosage)
• Pyrimidines (administration & dosage)
• Thiazoles (administration & dosage)